Nektar Therapeutics (NASDAQ: NKTR) is one of the best hot stocks to buy according to Wall Street analysts. On June 24, Nektar ...

A new immune-modulating treatment has shown promising results for treating moderate to severe eczema, delivering fast itch ...

Nektar’s shares have surged more than twofold after a Phase IIb study of its atopic dermatitis (AD) therapy rezpegaldesleukin ...

Figure skater Michelle Hong used to hide her skin as much as possible due to her condition—but with effective treatment and ...

Learn how Dupixent helps diverse eczema patients and why inclusive clinical trials are vital for fair healthcare.

Doctors report a steady increase in eczema cases among infants across Indian cities. Experts warn that genetics and ...

Nektar Therapeutics stock launched Tuesday after the biotech company hit every goal in a midstage study of its eczema ...

NKTR stock is up around 150% in today’s trading session following the recently announced positive results from its Phase 2b ...

Nektar Therapeutics shares doubled in early trading Tuesday after the U.S. biotech firm said it reached its targets in a midstage study of its eczema treatment.

In this video, Robert J. Smith, MD, discusses the many treatment options available to patients with atopic dermatitis.